The name polycystic ovary syndrome tells you that a woman has cysts on her ovaries. That has always been a problem, because polycystic ovary syndrome is not primarily a disease of ovarian cysts.
PCOS — the most common hormonal disorder in women of reproductive age, affecting an estimated 1 in 8 women worldwide, or more than 170 million people — is fundamentally a metabolic and hormonal condition. Its defining features are insulin resistance, androgen excess (elevated male sex hormones in female bodies), and irregular ovulation. The ovarian cysts that gave the condition its former name are actually small follicles that fail to mature properly as a result of the underlying hormonal disruption — they are a consequence of the real disorder, not its cause, and approximately 20 percent of women with the condition do not have the cysts at all.
That name has now been formally corrected. A global consensus process published in The Lancet on May 12, 2026 — involving 56 professional and patient organizations, iterative surveys with over 22,000 respondents, and more than a decade of debate — formally renamed the condition polyendocrine metabolic ovarian syndrome, or PMOS. The American Society for Reproductive Medicine, the Endocrine Society, and more than 50 other organizations have endorsed the new name. Rollout is planned over three years across guidelines used in 195 countries.
Why This Matters
Names in medicine are not just administrative labels. They shape how physicians think about a condition, which tests they order, which specialists they refer patients to, and what treatments they consider. PMOS — formerly PCOS — has historically produced a frustrating pattern of misdiagnosis and inadequate treatment that affects millions of women.
The typical clinical path for an undiagnosed PMOS patient:
She visits a gynecologist for irregular periods and is told to "just go on birth control" — which may regulate her periods but does not address the underlying metabolic dysfunction. She visits a dermatologist for acne or unwanted hair growth (hirsutism) and is treated symptomatically without connecting the symptoms to a systemic cause. She has an ultrasound, the radiologist sees polycystic-appearing ovaries, but the hormonal blood work is not ordered or interpreted in the right context. She is not screened for insulin resistance or pre-diabetes, conditions that affect a large proportion of PMOS patients and significantly increase long-term cardiovascular and metabolic risk.
This fragmented, symptom-by-symptom approach is partly driven by the disease's former name: if it is called a syndrome of ovarian cysts, it belongs in gynecology, which means the metabolic, endocrine, and cardiovascular dimensions can be overlooked.
An estimated 70% of women with PMOS are currently undiagnosed, according to the World Health Organization — a statistic that researchers directly link to the misleading name.
What PMOS Actually Is — and What the New Name Reflects
PMOS is a complex endocrine and metabolic disorder characterized by:
Androgen excess (elevated testosterone and related hormones): Causes hirsutism, acne, scalp hair thinning, and irregular ovulation. This is the most consistently present feature across PMOS patients and arguably the most important for diagnosis and treatment.
Ovulatory dysfunction: Irregular, infrequent, or absent ovulation causes irregular menstrual cycles. This is the most common reason women seek gynecological care for this condition.
Insulin resistance: Present in approximately 70 percent of women with PMOS, regardless of body weight, and a major driver of both the androgen excess and the long-term metabolic consequences. Insulin resistance in PMOS is associated with significantly elevated lifetime risk of type 2 diabetes, metabolic syndrome, and cardiovascular disease.
Polycystic ovarian morphology on ultrasound: Present in approximately 80 percent of women with PMOS — but also present in approximately 20 percent of women without the condition. Its presence is neither necessary nor sufficient for diagnosis.
The new name — polyendocrine metabolic ovarian syndrome — de-emphasizes the ovarian cysts and centers the actual pathophysiology. "Poly-endocrine" reflects that multiple endocrine pathways are involved. "Metabolic" captures the insulin resistance and cardiovascular implications. "Ovarian" and "syndrome" preserve the organ-level context and the multi-feature nature of the diagnosis.
The Diagnosis Gap the Misnomer Has Created
Studies consistently find that it takes an average of 2 to 3 years and multiple physician visits for women to receive a PMOS diagnosis. In some surveys, women report seeing 3 to 5 different physicians before receiving a correct diagnosis.
As Dr. Helena Teede, an endocrinologist at Monash University who led the renaming process, explained to CNN: "For too long, the name reduced a complex, long-term hormonal or endocrine disorder to a misunderstanding about 'cysts' and a focus on ovaries. This contributed to missed diagnoses and inaccurate treatment."
The name change, advocates argue, would make PMOS more recognizable as a systemic endocrine condition rather than a gynecological one — making it more likely to be identified, properly evaluated, and comprehensively treated.
What Doctors and Experts Say
Dr. Melanie Cree, a pediatric endocrinologist at the University of Colorado Anschutz who worked on the renaming, told TIME magazine: "The focus has often been on fertility and reproduction, at the expense of the other effects of the disorder. The majority of women don't get appropriate metabolic screening. That means that serious health problems can be missed, sometimes for years." The new name, she said, is intended to directly change that: "We're hoping it will change practice."
The renaming was chosen in a landslide — out of 90 voters, including doctors, researchers, patients, and advocates, 87 supported the new name immediately, with one more coming around before the manuscript was submitted.
What the Evidence Shows — and What It Does Not
The case for renaming PMOS is based on the documented mismatch between the name and the condition — not on any new clinical evidence about the condition itself. The condition, its pathophysiology, and its treatment are well-established. What the renaming reflects is clinical and scientific consensus that the existing name caused measurable harm through diagnostic delay and treatment fragmentation.
The evidence for what treatments work in PMOS is separate from the naming question: lifestyle modification targeting insulin resistance (diet and exercise), metformin for insulin resistance management, hormonal contraceptives for androgen suppression, and ovulation induction for fertility are the well-established treatment approaches. None of those treatment approaches will change because of the name change. What should change is how broadly physicians search for and recognize the condition.
What You Can Do Now
If you have irregular periods, unexplained acne or hirsutism, difficulty losing weight, or have been told your ovaries look "polycystic" on an ultrasound without a formal evaluation, ask your physician specifically about PMOS (formerly PCOS) — including blood tests for testosterone, LH/FSH ratio, insulin and glucose levels, and a full metabolic panel.
If you have been diagnosed with PCOS/PMOS, ask your physician whether you have been screened for insulin resistance and pre-diabetes — this is part of comprehensive PMOS management that is sometimes missed when the condition is seen primarily as a gynecological issue.
The Bottom Line
PCOS has been formally renamed PMOS — polyendocrine metabolic ovarian syndrome — in a landmark consensus process published in The Lancet on May 12, 2026, endorsed by the Endocrine Society, ASRM, and 50+ other organizations. The condition was always a misnomer. Its defining features — androgen excess, insulin resistance, and irregular ovulation — have been overshadowed for decades by a name that emphasized ovarian cysts, which are a consequence of the real disorder and absent in 20% of affected women. Experts say the new name could reduce the average 2-to-3-year diagnostic delay and push physicians to treat PMOS as the systemic metabolic condition it actually is.
